Fredrik Arp is proposed as board member in Nuevolution AB (publ)

Stockholm, 30 October 2017 – The Nomination committee in Nuevolution AB (publ) proposes to elect Fredrik Arp as board member at an extraordinary general meeting, and that the Board of directors thereby is increased from five to six members. The company will soon summon the shareholders in Nuevolution AB (publ) to an extraordinary meeting in Stockholm.

Nuevolution has planned a list change from Nasdaq First North Premier to Nasdaq Stockholm main market. This was announced in the press release on 18 September 2017 and is part of the company’s strategy “Grand plan – Reaching New Horizons”.

“A listing on the Nasdaq Stockholm main market is a major step for Nuevolution. In this context, we aim to strengthen the Board of directors with the experience that Fredrik Arp has from major public companies”, says David Sonnek, chairman of Nuevolution’s Nomination committee.

Fredrik Arp, 64 years, is one of Sweden’s most experienced business executives. In his most recent operational role he was managing director of Volvo Cars. He has even been CEO and managing director of Trelleborg AB (publ) and PLM AB. Fredrik Arp has considerable experience in medical technology, such as former board member of Getinge AB (publ) and Mediplast AB as well as in his role as chairman in Nolato AB (publ ). He is econ. dr. h.c. from Lund University where he also is chairman of the Advisory board at Lund’s School of Economics and Management (a part of Lund University).

”Nuevolution operates in a very exciting area and I have great respect for the company’s achievements in technology and research so far. Not least, the company’s business concept, drive and results have impressed me. It is with great pleasure that I accept this nomination as member of the Board of directors and I look forward to contributing with my experience to the company”, says Fredrik Arp.

”Our company is facing a new phase. Thus, it is with great pleasure that we can tie such an experienced and competent person as Fredrik Arp to our board. Fredrik Arp will contribute with his international network, deep industrial and financial knowledge and thereby support the process of taking Nuevolution to a new level”, says Stig Løkke Pedersen, Chairman in Nuevolution AB (publ).


For more information, please contact:

David Sonnek, chairman of the Nomination committee in Nuevolution AB (publ)
Tel.: +46 70 265 79 20

Stig Løkke Pedersen, chairman in Nuevolution AB (publ)
Tel.: +45 4086 4151


Information about Nuevolution AB (publ)

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on Monday 30 October 2017 at 08:45 CET.

Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on: